Drugaddamar da Magunguna Ibrutinib: Me Ka sani - AASraw
AASraw yana samar da NMN da NRC foda a cikin girma!

Ibrutinib

  1. Magunguna da Aka Yi niyya Ibrutinib (CAS: 936563-96-1)
  2. Tsarin Ibrutinib na Aiki
  3. Abinda ake Amfani da Ibrutinib
  4. Ibrutinib Fa'idodi / Tasirinsa
  5. Ta Yaya Zamu Ibauki Ibrutinib
  6. Ibrutinib Gurbin
  7. Adana Ibrutinib

Miyagun Kwayoyi Ibrutinib(CAS: 936563-96-1)

Yawancin sababbin magunguna don lymphoma sune ƙwayoyi masu niyya. Miyagun ƙwayoyi da nufin kashe nau'in kwayar halitta da ta juya ta cutar kansa ko dakatar da siginar da ke sa ƙwayoyin cutar kansa girma ko rarraba. A cikin kwayar halitta, ana kiran nau'in kwayar halitta wacce ta zama ta kansa "lymphocyte" (wani nau'in farin jini ne wanda ke yaƙar kamuwa da cuta). Akwai lymphocyte da yawa da zasu iya zama na kansa. Ibrutinib yana ƙaddamar da ƙwayoyin B (B ƙwayoyin) kuma saboda haka ana amfani dashi don magance ƙwayoyin B-cell.

Kwayoyin suna aikawa da karɓar sigina zuwa wasu ƙwayoyin. Wasu daga cikin waɗannan alamun suna rayar da ƙwayoyin rai kuma suna sanya su rarrabuwa. Akwai hanyoyi da yawa na sigina kuma ana aika sigina tare ɗaya ko fiye daga waɗannan hanyoyin. Ibrutinib shine mai toshe siginar kwayar halitta wanda ke nufin furotin da ake kira 'Bruton' s tyrosine kinase '(BTK). BTK wani ɓangare ne na hanyar da ke taimakawa ƙwayoyin B su ci gaba da rayuwa da rarrabawa. Toshewar BTK na iya sa ƙwayoyin B su mutu ko hana su rarraba. Don haka wannan maganin na iya dakatar da yaduwar kwayoyin cutar kansa.

 

Ibrutinib Kayan aikin

Ibrutinib (936563-96-1) ba magani ne na magani ba amma ɗayan da ake kira “hanyoyin kwantar da hankali.” Farfaɗar da aka ƙaddara sakamakon shekaru ne na bincike wanda aka keɓe don fahimtar bambance-bambance tsakanin kwayoyin cutar kansa da ƙwayoyin al'ada. Zuwa yau, maganin cutar kansa ya fi mai da hankali kan saurin rarraba ƙwayoyin halitta saboda fasali ɗaya na ƙwayoyin kansa shi ne cewa suna saurin rarrabawa. Abun takaici, wasu daga cikin kwayoyin mu na yau da kullun sun rabu da sauri, suna haifar da sakamako mai yawa.

Tsarin da aka kera shi ne game da gano wasu siffofin kwayoyin cutar ciwon daji. Masana kimiyya suna nema bambance-bambance daban-daban a cikin kwayoyin cutar kanjamau da kuma kwayoyin halitta. Ana amfani da wannan bayanin don ƙirƙirar farfado da aka yi nufi don kai hari ga kwayoyin cutar ciwon daji ba tare da lalata kwayoyin halitta ba, saboda haka ya haifar da ƙananan sakamako. Kowace nau'in farfadowa da aka yi niyyar aiki kaɗan kaɗan amma duk yana tsangwama tare da ikon ciwon kwayar halitta don yayi girma, raba, gyara da / ko sadarwa tare da wasu kwayoyin halitta.

Ibrutinib yana hana aikin Bruton's tyrosine kinase (BTK). BTK shine mabuɗin siginar siginar siginar siginar karɓar rayayyun ƙwayoyin B wanda ke taka muhimmiyar rawa wajen rayuwa da ƙwayoyin ƙwayoyin B masu haɗari. Ibrutinib yana toshe siginonin da ke haifar da mugayen kwayoyin B don girma da rarrabawa ba tare da kulawa ba. Bincike ya ci gaba da gano waɗanne cututtukan da za a iya amfani da su da kyau tare da hanyoyin magance su da kuma gano ƙarin maƙasudin don ƙarin nau'in cutar kansa.

Lura: Muna ƙarfafa ku sosai don yin magana da ƙwararrun likitanku game da takamaiman yanayin lafiyarku da jiyya. Bayanin da ke cikin wannan rukunin yanar gizon yana nufin taimako da ilimantarwa, amma ba maye gurbin shawarar likita ba.

AASraw ƙwararren masani ne na Ibrutinib.

Da fatan za a danna nan don bayanin zance: Saduwa da mu

 

Abinda ake Amfani da Ibrutinib

Don kula da mutanen da ke fama da cutar sankara ta jiki (MCL; ciwon daji mai saurin girma wanda ke farawa a cikin ƙwayoyin garkuwar jiki) waɗanda tuni aka ba su magani tare da aƙalla ɗayan sauran magunguna na chemotherapy.

Kula da mutane da na kullum lymphocytic cutar sankarar bargo (CLL; wani nau'in ciwon daji ne da ke farawa a cikin ƙwayoyin farin jini) da ƙananan ƙwayoyin lymphocytic lymphoma (SLL; wani nau'in ciwon daji wanda yake farawa galibi a cikin ƙwayoyin lymph).

Don magance mutane tare da Waldenstrom macroglobulinemia (WM; ciwon daji mai saurin tashi wanda ke farawa a cikin wasu ƙwayoyin farin jini a cikin kashin ku).

Treat Don kula da mutanen da ke fama da cutar lymphoma (MZL; ciwon daji mai saurin girma wanda ke farawa a cikin wani nau'in ƙwayoyin jini waɗanda ke yaƙar kamuwa da cuta) waɗanda aka riga aka bi da su da wani nau'in magani na chemotherapy.

Don kula da mutanen da ke fama da cututtukan da ba a yarda da su ba (cGVHD; wani mawuyacin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jini [HSCT; hanyar da za ta maye gurbin ƙwayar cuta tare da ƙashi mai lafiya] wanda zai iya farawa dan lokaci bayan dasa shi kuma ya daɗe na dogon lokaci ) bayan an magance ba tare da nasara ba tare da magunguna 1 ko fiye.

Ibrutinib yana cikin aji na magungunan da ake kira masu hana motsi. Yana aiki ta hanyar toshe aikin sunadarin da ba shi da kyau wanda ke nuna ƙwayoyin kansar su ninka. Wannan yana taimakawa dakatar da yaduwar kwayoyin cutar kansa.

Ibrutinib

Ibrutinib amfanin/ Tasirin

Ibrutinib masana da yawa suna ɗaukarsa azaman 'magani mai nasara' ga wasu nau'ikan cutar lymphoma. Yana ba da ƙimar amsawa mafi girma idan aka kwatanta da sauran hanyoyin kwantar da hankali don nau'ikan ƙwayoyin cuta iri ɗaya. Babban gwajin da ya haifar da yardar ibrutinib an bayyana shi a taƙaice a ƙasa.

 

(1) Fa'idodi a cikin kwayar halitta ta kwayar halitta

Kwayar lymphoma ta Mantle wacce ta sake dawowa ko ba ta amsa ba ga layin farko na iya zama da wahalar magani. Koyaya, babban binciken a wannan yankin ya nuna cewa fiye da kashi biyu bisa uku na mutanen 111 da aka kula da su tare da ibrutinib sun amsa maganin (lymphoma ɗinsu ya ragu ko ya ɓace).

Nazari na biyu a cikin mutane 280 ya kwatanta ibrutinib tare da wani magani na kansar, temsirolimus, a cikin mutanen da ke fama da sake komowa ko ƙin shiga kwayar halittar alkunya. Mutane sun rayu na tsawon watanni 15 ba tare da kwayar cutar ta lymphoma ba ta kara tabarbarewa lokacin da aka bi da su da ibrutinib idan aka kwatanta da matsakaita na watanni 6 lokacin da aka bi da su da temsirolimus.

 

(2) Fa'idodi a cikin cutar sankarar bargo lymphocytic (CLL)

An ga maganganun dogon lokaci a cikin mutane tare da CLL waɗanda aka bi da su tare da ibrutinib. A cikin babban gwajin da ya shafi mutane 391 tare da sake komawa baya ko ƙi CLL, ibrutinib ya kasance idan aka kwatanta da ofatumumab, wanda galibi ana amfani dashi ga mutanen da ke da CLL wanda ya dawo. Shekara guda bayan fara magani, kusan 66 a cikin 100 mutane da ke shan ibrutinib suna da CLL wanda ya kasance ƙarƙashin iko (wannan ana kiransa 'rayuwa ba tare da ci gaba ba') idan aka kwatanta da kusan 6 a cikin 100 mutane da aka kula da ofatumumab.

A cikin bincike na biyu wanda ya shafi mutane 269 wadanda har yanzu basu sami wani magani ba na CLL, ibrutinib ya kasance idan aka kwatanta da chlorambucil chemotherapy. Bayan shekaru 1.5 na jinya, kusan 90 a cikin mutane 100 da ke shan ibrutinib suna da CLL wanda ya kasance a ƙarƙashin iko idan aka kwatanta da kusan 52 a cikin 100 mutane da aka kula da chlorambucil.

Ara ibrutinib zuwa bendamustine da rituximab ga mutanen da suka sake komawa baya ko suka ƙi CLL shima ya yi tasiri a cikin binciken da ya shafi mutane 578. Hadarin cigaban CLL ya ragu ta hanyar shan ibrutinib a maimakon placebo (magani mai danshi).

 

(3) Fa'idodi a cikin Waldenström' s macroglobulinaemia (WM)

Hakanan an ga ƙimar amsawa mai yawa a cikin mutane masu WM - kusan 9 cikin 10 mutane da WM sun amsa ibrutinib magani a cikin gwaji a cikin mutane 63. Wannan gwajin ya kasance gagarumar nasara ga WM saboda yana da wani sabon abu na lymphoma kuma saboda haka yana da wahala a tara mutane da yawa don shiga cikin gwajin asibiti. Wannan gwajin ya haifar da yardar ibrutinib na WM a Turai.

 

Ta Yaya Zamu dauka Ibrutinib 

Za'a baku ibrutinib a matsayin Allunan. Ana iya bayar da shi a haɗe tare da wasu magungunan maganin da aka yi niyya da chemotherapy. Yayin jinya yawanci kuna ganin likitan kansar, mai kula da cutar kansa ko ƙwararren likita, da ƙwararren likitan magunguna. Wannan shine wanda muke nufi idan muka ambaci likita, likita ko likitan magunguna a cikin wannan bayanin.

Kafin ko a ranar jiyya, nas ko mutumin da aka horar don shan jini (phlebotomist) zai ɗauki samfurin jini daga gare ku. Wannan don bincika cewa ƙwayoyin jininka suna cikin matakin aminci don samun magani.

Za ku ga likita ko likita kafin a ba ku magani. Za su tambaye ku yadda kuka ji. Idan sakamakon jininku yayi kyau, likitan magunguna zai shirya maganin ku. M nas zai gaya muku lokacin da magani zai iya zama a shirye.

Ma’aikacin jinya ko likitan magunguna zai baku allunan ibrutinib don kai gida. Koyaushe dauke su daidai kamar yadda aka bayyana. Wannan yana da mahimmanci don tabbatar da cewa sunyi aiki kamar yadda ya yiwu a gare ku. Za a iya ba ku allunan ƙarfi daban-daban. Kullum kuna kiyaye shan ibrutinib kowace rana har tsawon lokacin da yake kiyaye ciwon daji. Ma'aikatan jinya ko likitan magunguna na iya ba ku magungunan rigakafin cuta da sauran magunguna don komawa gida. Allauki allunanka duka yadda aka bayyana maka su.

AASraw ƙwararren masani ne na Ibrutinib.

Da fatan za a danna nan don bayanin zance: Saduwa da mu

 

Tunatarwa akan Kula da Kai

Yayin shan ibrutinib, ka sha aƙalla ruwa kusan lita biyu zuwa uku a kowane awa 24, sai dai in an baka umarnin akasin hakan.

Ash Wanke hannuwan ka sau da yawa kuma bayan shan kowane maganin ibrutinib.

May Kuna iya kasancewa cikin haɗarin kamuwa da cuta don haka yi ƙoƙari ku guji taron jama'a ko mutane masu mura, kuma ku ba da rahoton zazzaɓi ko wasu alamun kamuwa da cuta nan da nan ga mai ba ku kiwon lafiya.

♦ Don taimakawa magance / hana ciwon baki yayin shan ibrutinib, yi amfani da buroshin hakori mai taushi, sannan a kurkura sau uku a rana da karamin cokalin shan soda guda daya wanda aka gauraya da ruwa na ruwa 1.

♦ Yi amfani da reza lantarki da burushi mai taushi don rage zubar jini.

♦ Guji wasannin saduwa ko ayyukan da zasu iya haifar da rauni.

♦ Domin rage tashin zuciya, shan magungunan tashin zuciya kamar yadda likitanka ya bada umarni, kuma ka ringa cin abinci kadan, mai yawa yayin shan ibrutinib.

At Ci abinci wanda zai iya taimakawa rage rage gudawa-duba Gudanar da Illolin Gudawa - Gudawa

♦ Bi tsari na maganin cutar gudawa kamar yadda kwararrun likitocin ku suka tsara.

Guji bayyanar rana. Sanya SPF 15 (ko mafi girma) toshewar rana da tufafi masu kariya. Ibrutinib na iya sanya ka zama mai saurin jin rana kuma zaka iya kunar rana a sauƙaƙe.

♦ Gabaɗaya, shan giya ya zama mafi ƙaranci ko a guje shi gabadayan lokacin shan ibrutinib. Ya kamata ku tattauna wannan tare da likitan ku.

Samu hutu sosai.

Kula da abinci mai kyau yayin da ake bi da ku tare da ibrutinib.

Idan kun sami bayyanar cututtuka ko sakamako masu illa yayin da ake bi da ku tare da ibrutinib, tabbatar da tattauna su tare da ƙungiyar kula da lafiyar ku. Zasu iya rubuta magunguna da / ko bayar da wasu shawarwari waɗanda ke da tasirin sarrafa waɗannan matsalolin.

 

Ibrutinib Sa nan Eilla

Samun taimakon likita na gaggawa idan kana da alamun rashin lafiyar abu; wuya numfashi; busa fuskarka, lebe, harshe, ko wuya.

 

Dakatar da ibrutinib sannan ka kira likitanka kai tsaye idan kana da:

Alamomin kamuwa da cuta – zazzabi, sanyi, rauni, rauni na baki, tari tare da lakar, matsalar numfashi;

♦ Alamun zubda jini a cikin jikinku - damuwa, rauni, rudani, matsaloli na magana, doguwar ciwon kai, kujerun baƙar fata ko na jini, ruwan fitsari mai ruwan hoda ko ruwan kasa, ko tari na jini ko amai wanda yake kaman filawar kofi;

Diarrhea Ciwon mai tsanani ko mai gudana;

Pain Ciwon kirji, bugawar bugun zuciya ko jujjuyawa a kirjinka, jin kamar zaka wuce;

Headache Ciwon kai mai tsanani, hangen nesa, bugawa a wuya ko kunnuwa;

♦ Rauni mai sauƙi, zub da jini na ban mamaki, shuɗi mai launi ko ja a ƙarƙashin fatarku;

Skin Fata mai haske, hannaye masu sanyi da ƙafa;

Problems Matsalar koda - kaɗan ko kaɗan yin fitsari, kumburi a ƙafafunku ko idon sawunku; ko

Alamar fashewar kwayar cuta-rikicewa, rauni, ciwon jiji, tashin zuciya, amai, saurin ko saurin bugun zuciya, rage fitsari, kunci a hannayenku da kafafuwanku ko a bakinku.

 

Hanyoyin cutar na iya haɗawa da su:

Arrhea gudawa, tashin zuciya;

Ever Zazzabi, tari, matsalar numfashi;

♦ Buruji ko marurai a cikin bakinka;

Tired Jin kasala;

Ising Bruising, kurji; ko

Pain Ciwan jijiyoyi, ciwon kashi.

Wannan ba cikakken lissafi ne na sakamakon lalacewa ba kuma wasu zasu iya faruwa. Kira likitan ku don shawara na likita game da illa mai lalacewa. Kuna iya bayar da rahoton abubuwan lalacewa zuwa FDA a 1-800-FDA-1088.

AASraw ƙwararren masani ne na Ibrutinib.

Da fatan za a danna nan don bayanin zance: Saduwa da mu

 

Ibrutinib Storage

Sanya Ibrutinib a cikin akwatin da ya shigo, a rufe sosai, kuma daga inda yara zasu isa. Ajiye shi a zafin jiki na ɗaki kuma nesa da haske, yawan zafin rana da danshi ba cikin gidan wanka ba.

Ya kamata a zubar da Ibrutinib da ba a buƙata ta hanyoyi na musamman don tabbatar da cewa dabbobin gida, yara, da sauran mutane ba za su iya cinye su ba. Koyaya, bai kamata ku zubar da wannan Ibrutinib a bayan gida ba. Madadin haka, hanya mafi kyau don zubar da maganinku shine ta hanyar shirin dawo da magani. Yi magana da likitan ka ko ka tuntuɓi sashen shara / sake amfani da shara don sanin shirye-shiryen dawo da martabar ku a cikin al'ummarku. Duba Tsarin Lafiya na FDA na

Yana da muhimmanci a kiyaye dukkan maganin da ba a gani da kuma isa ga yara kamar kwantena da yawa (irin su jariri da kullun mako daya da wadanda ke da idanu, creams, patches, and inhalers) ba su da yarinya kuma yara masu iya buɗe su sauƙi. Don kare yaran yara daga guba, kulle kullun lafiya kuma sanya wuri a cikin wuri mai aminci - wanda ke sama da tafi da kuma daga idanunsu kuma ya isa.

 

reference

[1] Brown JR, Hillmen P, O'Brien S, et al. Addamar da bibiya da tasirin abubuwan haɗari masu haɗari daga binciken na 3 RESONATE a cikin marasa lafiya tare da CLL / SLL da aka kula da su a baya [wanda aka buga a kan layi kafin bugawa 8 Yuni 2017]. Ciwon sankarar jini

[2] Byrd JC, Brown JR, O'Brien S, et al; SAKAMAKON masu bincike. Ibrutinib da ofatumumab a cikin cutar sankarar bargo ta lymphoid ta yau da kullun. N Engl J Med. 2014; 371 (3): 213-223.

[3] Byrd JC, Furman RR, Coutre SE, et al. Kulawa na shekaru uku na rashin kulawa da marasa lafiya tare da CLL da SLL masu karɓar ibrutinib guda ɗaya. Jini. 2015; 125 (16): 2497-2506.

[4] Mato AR, Hill BT, Lamanna N, et al. Tsarin mafi kyau na ibrutinib, idelalisib, da venetoclax a cikin cutar sankarar jini na lymphocytic na yau da kullun: sakamakon daga binciken da yawa na marasa lafiya 683. Ann Oncol. 2017; 28 (5): 1050-1056.

[5] Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-tsayayyar matsakaici zuwa ibrutinib a cikin cutar sankarar bargo ta lymphocytic. J Clin Oncol. 2017; 35 (13): 1437-1443.

[6] Winqvist M, Asklid A, Andersson PO, et al. Sakamakon duniya na ibrutinib a cikin marasa lafiya tare da sake dawowa ko cutar sankarar bargo ta lymphocytic: bayanai daga marasa lafiya 95 a jere da aka bi da su a cikin shirin amfani da jin kai. Nazarin daga Swedishungiyar Yaren mutanen Sweden Chronic Lymphocytic Leukemia Group. Haematologica. 2016; 101 (12): 1573-1580.

[7] Jones JA, Hillmen P, Coutre S, et al. Amfani da magungunan hana daukar ciki da kuma maganin hana yaduwar cuta a marasa lafiya tare da cutar sankarar bargo ta lymphocytic na yau da kullun tare da wakilin ibrutinib guda daya. Br J Haematol. 2017; 178 (2): 286-291.

[8] Kamel S, Horton L, Ysebaert L, da sauransu. Ibrutinib yana hana jigilar kwayar cutar collagen amma ba ADP ba. Ciwon sankarar jini 2015; 29 (4) 783-787.

[9] Rigg RA, Aslan JE, Healy LD, et al. Gudanar da baki na masu hana maganin tyrosine kinase na lalata aikin platelet mai sassaucin ra'ayi na GPVI. Am J Physiol Cell din Physiol. 2016; 310 (5): C373-C380.

[10] Wang ML, Rule S, Martin P, et al. Neman BTK tare da ibrutinib a cikin sake komowa ko ƙyamar kwayar cutar sankarau. N Engl J Med. 2013; 369 (6): 507-516.

[11] Treon SP, Tripsas CK, Meid K, et al. Ibrutinib a cikin maganin da aka yi wa Waldenström na macroglobulinemia. N Engl J Med. 2015; 372 (15): 1430-1440.

[12] Lampson BL, Yu L, Glynn RJ, et al. Hywararriyar ƙwayar iska da mutuwa kwatsam a cikin marasa lafiyar da ke shan ibrutinib. Jini. 2017; 129 (18): 2581-2584.

[13] Tedeschi A, Frustaci AM, Mazzucchelli M, Cairoli R, Montillo M. Shin ana buƙatar prophylaxis na HBV yayin maganin CLL tare da ibrutinib? Leuk Lymphoma. 2017; 58 (12): 2966-2968.

[14] Sun C, Tian X, Lee YS, et al. Sake sake dawo da rigakafin wariyar launin fata da ƙananan cututtuka a marasa lafiya tare da cutar sankarar bargo ta lymphocytic wanda aka kula da shi tare da ibrutinib. Jini. 2015; 126 (19): 2213-2219.

[15] Ruchlemer R, Ben Ami R, Lachish T. Ibrutinib don cutar sankarar bargo ta lymphocytic. N Engl J Med. 2016; 374 (16): 1593-1594.

[16] Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii ciwon huhu a cikin marasa lafiya da ba a kula da su ba tare da CLL a kan wakili ɗaya ibrutinib. Jini. 2016; 128 (15): 1940-1943.

[17] Vitale C, Ahn IE, Sivina M, et al. Autoimmune cytopenias a cikin marasa lafiya tare da cutar sankarar bargo lymphocytic na yau da kullun tare da ibrutinib. Haematologica. 2016; 101 (6): e254-e258.

[18] Lebe GY, Pan X, Kamble S, et al. Babban haɗarin zubar da jini tsakanin marasa lafiya marasa ƙarfi wanda aka fara akan apixaban, dabigatran, rivaroxaban ko warfarin: nazarin duniya "na zahiri" a Amurka. Int J Clin Pract. 2016; 70 (9): 752-763.

0 Likes
155 Views

Za ka iya kuma son

Comments an rufe.